Vaxcyte Inc

NASDAQ:PCVX   3:59:52 PM EDT
24.42
+0.39 (+1.62%)
Products

Vaxcyte Completes Enrollment Of Phase 2 Study Evaluating Safety, Tolerability And Immunogenicity Of Vax-24

Published: 09/06/2022 21:24 GMT
Vaxcyte Inc (PCVX) - Vaxcyte Completes Enrollment of Phase 2 Study Evaluating Safety, Tolerability and Immunogenicity of Vax-24 in Adults 65 Years and Older.
Vaxcyte Inc - Expects to Announce Topline Data From Study in Adults 65 Years and Older in First Half of 2023.
Vaxcyte - on Track to Announce Topline Data From Phase 1 and Phase 2 Portions of Vax-24 Proof-of-concept Study in Adults Aged 18-64 in Oct Or Nov 2022.